We are thrilled to share a landmark win for the Australian myasthenia gravis (MG) community: the Pharmaceutical Benefits Advisory Committee (PBAC) has officially recommended all four new MG treatments for listing on the Pharmaceutical Benefits Scheme (PBS). This recognition of the high and unmet clinical need, announced following the March 2025 PBAC meeting, is a powerful validation of the advocacy efforts led by patients, carers, and clinicians.

Key highlights:

• Applies to adults with generalized MG (gMG) who are AChR antibody-positive
• Implementation by government departments is underway (PBS access expected in coming months)
• Limited early access may be available via pharmaceutical company programs
• MAA continues to advocate for patients outside the listed parameters

We thank our community - your lived experience made this outcome possible.

📄 Read the full breakdown of this historic achievement below